Search Results

Dallas-based board-certified dermatologist Seemal R. Desai, MD, FAAD, will begin his one-year term as president of the American Academy of Dermatology at the close of the AAD’s Annual Meeting.

Galderma, the pure-play dermatology category leader, will be showcasing its latest clinical and educational efforts at the American Academy of Dermatology Annual Meeting from March 8-12, 2024, highlighting its broad, innovative and leading dermatology portfolio.

Incyte (Nasdaq:INCY) today announced multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2024 American Academy of Dermatology (AAD) Annual Meeting, held March 8-12, 2024, in San Diego.

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

Sofwave Medical Ltd is excited to announce its participation at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

SkinCure Oncology presented to dermatology patients as the GentleCure™ Experience, is exhibiting at the American Academy of Dermatology annual meeting in San Diego March 8-12, and unveiling a groundbreaking new technology for the noninvasive treatment of common skin cancers.

Kyowa Kirin Co., Ltd. announced that disease education and data from the Phase 2b study of rocatinlimab, an investigational product being studied in patients with moderate-to-severe atopic dermatitis, will be presented at the upcoming American Academy of Dermatology 2024 Annual Meeting in San Diego from March 8-12, 2024.

Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio – SB5, a biosimilar to Humira, and SB17, a proposed biosimilar to Stelara2 – at the 2024 American Academy of Dermatology Annual Meeting being held from March 8 to 12 in San Diego, California, United States.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced five presentations at the 2024 American Academy of Dermatology (AAD) annual meeting, which will take place in San Diego, CA from March 8 - 12, 2024.

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that post-hoc analysis data from the Phase 2b study of rocatinlimab (AMG 451/KHK4083), an investigational product in patients with moderate-to-severe atopic dermatitis (msAD), will be presented at the American Academy of Dermatology (AAD) 2024 Annual Meeting to be held in San Diego from March 8-12, 2024.